The U.S. Food and Drug Administration approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Varubi is approved in adults in combination with other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results